We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
PURITAN MEDICAL

Download Mobile App




Viral Marker Predicts Flu Severity in Infected Patients

By LabMedica International staff writers
Posted on 01 Nov 2017
Influenza A viruses are the causative agents of annual epidemics, sporadic zoonotic outbreaks and occasionally pandemics. More...
Worldwide, acute respiratory infections caused by influenza A viruses continue to be one of the main causes of acute illness and death.

Influenza is particularly dangerous for infants, the elderly, and people with underlying medical issues, but otherwise-healthy people sometimes experience severe infection, too. Markers of severity have been found for specific strains, but a general marker that applies to multiple strains would be more useful to inform treatment and policy.

A team of scientists at the Spanish National Center for Biotechnology (Madrid, Spain) included in their study patients in a severe/fatal cohort who were influenza A(H1N1)pdm09 confirmed cases, aged over four and less than 65 years old, admitted to intensive care unit (ICU) and with the information related to risk factors reflected in their clinical history. Those patients who developed highly severe disease did not display any comorbidities associated to severe influenza A virus infection, and deceased patients presented some comorbid conditions. Mild patients were influenza A(H1N1)pdm09 confirmed cases, aged over four and less than 65 years old, who developed mild disease and were monitored by sentinel medical centers.

The team focused on defective viral genomes (DVGs), which consist of pieces of viral RNA with missing genetic information, which are found in multiple strains of influenza virus. To test whether DVGs could serve as a general marker of influenza severity, they infected both mice and human tissue cell cultures with different strains of influenza A H1N1 virus, the subtype responsible for influenza pandemics.

The team also analyzed the genomes of viruses isolated from respiratory samples taken from people who experienced severe infection or death during the 2009 "swine flu" pandemic or later "swine flu-like" seasons. The identity of rescued mutant viruses was ascertained by sequencing of DNAs derived from the polymerase genes PA and PB2 RNA segments by reverse transcription-PCR (RT-PCR) amplification. Quality and quantity of each RNA preparation was monitored using the Agilent 2100 Bioanalyzer. Flow cytometric analysis was performed on a cytometer LSR II.

The team found that the H1N1 strain that caused severe symptoms had significantly less DVG accumulation than influenza A strains sampled from people who experienced only mild symptoms. Together, these results suggest that low levels of DVGs may indicate greater risk of severe disease in patients infected with influenza A virus. With further studies, these findings could help predict influenza severity, guide patient treatment, and inform influenza prevention strategies. The study was published on October 12, 2017, in the journal Public Library of Sciences Pathogens.

Related Links:
Spanish National Center for Biotechnology


New
Gold Member
Quality Control Material
iPLEX Pro Exome QC Panel
3-Part Differential Hematology Analyzer
Swelab Alfa Plus Sampler
New
Gold Member
Blood Gas Analyzer
Stat Profile pHOx
New
Candida Glabrata Test
ELIchrom Glabrata
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








DIASOURCE (A Biovendor Company)

Channels

Molecular Diagnostics

view channel
Image: The RNA-seq based diagnostic test for pediatric leukemia ensures better outcomes for children with this common cancer (Photo courtesy of Qlucore)

RNA-Seq Based Diagnostic Test Enhances Diagnostic Accuracy of Pediatric Leukemia

A new unique test is set to reshape the way Acute Lymphoblastic Leukemia (BCP-ALL) samples can be analyzed. Qlucore (Lund, Sweden) has launched the first CE-marked RNA-seq based diagnostic test for pediatric... Read more

Hematology

view channel
Image: CitoCBC is the world first cartridge-based CBC to be granted CLIA Waived status by FDA (Photo courtesy of CytoChip)

Disposable Cartridge-Based Test Delivers Rapid and Accurate CBC Results

Complete Blood Count (CBC) is one of the most commonly ordered lab tests, crucial for diagnosing diseases, monitoring therapies, and conducting routine health screenings. However, more than 90% of physician... Read more

Immunology

view channel
Image: A simple blood test could replace surgical biopsies for early detecion of heart transplant rejection (Photo courtesy of Shutterstock)

Blood Test Detects Organ Rejection in Heart Transplant Patients

Following a heart transplant, patients are required to undergo surgical biopsies so that physicians can assess the possibility of organ rejection. Rejection happens when the recipient’s immune system identifies... Read more
Copyright © 2000-2025 Globetech Media. All rights reserved.